Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Did anyone notice recently that Lisa Bauman, VP of Clinical Operations is no more at Zenith?
https://www.zenithepigenetics.com/about/management
https://theorg.com/org/zenith-epigenetics/org-chart/lisa-bauman